Compare ISSC & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISSC | IMRX |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.6M | 320.3M |
| IPO Year | 2000 | 2021 |
| Metric | ISSC | IMRX |
|---|---|---|
| Price | $20.27 | $5.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $16.50 | ★ $17.20 |
| AVG Volume (30 Days) | 772.5K | ★ 802.2K |
| Earning Date | 05-13-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 37.75 |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.63 | N/A |
| Revenue Next Year | $8.13 | N/A |
| P/E Ratio | $88.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.30 | $1.10 |
| 52 Week High | $30.98 | $10.08 |
| Indicator | ISSC | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 52.50 |
| Support Level | $17.57 | $4.83 |
| Resistance Level | $22.60 | $5.36 |
| Average True Range (ATR) | 2.13 | 0.29 |
| MACD | -1.36 | -0.00 |
| Stochastic Oscillator | 11.69 | 53.40 |
Innovative Solutions and Support Inc is a systems integrator that designs, manufactures, sells, and services air data equipment, engine display systems, standby equipment, primary flight guidance, and cockpit display systems for retrofit applications and original equipment manufacturers. The company supplies integrated Flight Management Systems, Flat Panel Display Systems, Integrated Standby Units, Positioning System receivers that enable reduced carbon footprint navigation, and an Autothrottle, which allows a pilot to automatically control the power setting of the engine and is designed to reduce pilot workload and enhance safety. It sells its products to both the OEM and the retrofit markets.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.